Beta Bionics, Inc.
For the period ended Jun 30, 2025. Filed Jul 29, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Jul 29, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plan
Duringthe three months ended June 30, 2025, the following officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted orterminated the contracts, instructions or written plans for the purchase or sale of the Company’s securities set forth in the table below.
| Name and Position | Action | Date | Rule 10b5-1* | Total Shares to be Sold | Expiration Date |
|---|---|---|---|---|---|
| Mark Hopman, Chief Commercial Officer | Adoption | May 13, 2025 | X | 32,318 | August 18, 2026 |
| Stephen Feider, Chief Financial Officer | Adoption | May 15, 2025 | X | 80,000 | June 30, 2026 |
| * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.